Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% | -.--% | -.--% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company benefits from high valuations in earnings multiples.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 10.9B | - | ||
+34.14% | 51.12B | B- | ||
-6.54% | 39.4B | B | ||
+34.92% | 38.48B | A | ||
+12.62% | 26.36B | B- | ||
-12.11% | 26.22B | C | ||
-13.43% | 20.96B | B | ||
+43.73% | 14.02B | B+ | ||
+31.81% | 12.49B | C+ | ||
-4.54% | 11.61B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CRL Stock
- RV6 Stock
- Ratings Charles River Laboratories International, Inc.